Metabolic syndrome and robustness tradeoffs

被引:93
作者
Kitano, H
Oda, K
Kimura, T
Matsuoka, Y
Csete, M
Doyle, J
Muramatsu, M
机构
[1] Sony Comp Sci Labs Inc, Tokyo 1410022, Japan
[2] Syst Biol Inst, Tokyo, Japan
[3] Keio Univ, Tokyo, Japan
[4] Tokyo Med & Dent Univ, Med Res Inst, Tokyo, Japan
[5] Japan Sci & Technol Agcy, ERATO, SORST, Kitano Symbiot Syst Project, Tokyo, Japan
[6] Emory Univ, Dept Anesthesiol, Atlanta, GA 30322 USA
[7] CALTECH, Pasadena, CA 91125 USA
关键词
D O I
10.2337/diabetes.53.suppl_3.S6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The metabolic syndrome is a highly complex breakdown of normal physiology characterized by obesity, insulin resistance, hyperlipidemia, and hypertension. Type 2 diabetes is a major manifestation of this syndrome, although increased risk for cardiovascular disease (CVD) often precedes the onset of frank clinical diabetes. Prevention and cure for this disease constellation is of major importance to world health. Because the metabolic syndrome affects multiple interacting organ systems (i.e., it is a systemic disease), a systems-level analysis of disease evolution is essential for both complete elucidation of its pathophysiology and improved approaches to therapy. The goal of this review is to provide a perspective on systems-level approaches to metabolic syndrome, with particular emphasis on type 2 diabetes. We consider that metabolic syndromes take over inherent dynamics of our body that ensure robustness against unstable food supply and pathogenic infections, and lead to chronic inflammation that ultimately results in CVD. This exemplifies how trade-offs between robustness against common perturbations (unstable food and infections) and fragility against unusual perturbations (high-energy content foods and low-energy utilization lifestyle) is exploited to form chronic diseases. Possible therapeutic approaches that target fragility of emergent robustness of the disease state have been discussed. A detailed molecular interaction map for adipocyte, hepatocyte, skeletal muscle cell, and pancreatic beta-cell cross-talk in the metabolic syndrome can be viewed at http://www.systems-biology.org/001/003.html.
引用
收藏
页码:S6 / S15
页数:10
相关论文
共 71 条
  • [1] Clinical use of thiazolidinediones: Recommendations
    Abrahamson, MJ
    [J]. AMERICAN JOURNAL OF MEDICINE, 2003, 115 : 116 - 120
  • [2] Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
  • [3] 2-S
  • [4] Robustness in bacterial chemotaxis
    Alon, U
    Surette, MG
    Barkai, N
    Leibler, S
    [J]. NATURE, 1999, 397 (6715) : 168 - 171
  • [5] Journey from cachexia to obesity by TNF
    Argiles, JM
    LopezSoriano, J
    Busquets, S
    LopezSoriano, FJ
    [J]. FASEB JOURNAL, 1997, 11 (10) : 743 - 751
  • [6] Robustness in simple biochemical networks
    Barkai, N
    Leibler, S
    [J]. NATURE, 1997, 387 (6636) : 913 - 917
  • [7] Bondeson J, 2001, INT J CLIN PRACT, V55, P211
  • [8] Biochemistry and molecular cell biology of diabetic complications
    Brownlee, M
    [J]. NATURE, 2001, 414 (6865) : 813 - 820
  • [9] Tumour necrosis factor, a key role in obesity?
    Bulló-Bonet, M
    García-Lorda, P
    López-Soriano, FJ
    Argilés, JM
    Salas-Salvadó, J
    [J]. FEBS LETTERS, 1999, 451 (03) : 215 - 219
  • [10] Highly optimized tolerance: A mechanism for power laws in designed systems
    Carlson, JM
    Doyle, J
    [J]. PHYSICAL REVIEW E, 1999, 60 (02): : 1412 - 1427